Currently, no pharmacological therapies are approved for the treatment of NASH. A new study now identifies CASP8 and FADD-like apoptosis regulator (CFLAR) as a novel suppressor of NASH and its associated disorders in a process dependent on the activation of apoptosis signal-regulating kinase 1 (ASK1).
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wree, A., Broderick, L., Canbay, A., Hoffman, H. M. & Feldstein, A. E. From NAFLD to NASH to cirrhosis — new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 10, 627–636 (2013).
Feldstein, A. E. et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437–443 (2003).
Li, H. et al. Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice. Hypertension 56, 1109–1117 (2010).
Wang, P.-X. et al. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nat. Med. http://dx.doi.org/10.1038/nm.4290, (2017).
Sakauchi, C., Wakatsuki, H., Ichijo, H. & Hattori, K. Pleiotropic properties of ASK1. Biochim. Biophys. Acta 1861, 3030–3038 (2017).
Xiang, M. et al. Targeting hepatic TRAF1–ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. J. Hepatol. 64, 1365–1377 (2016).
Xie, L. et al. DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity. J. Hepatol. 65, 113–124 (2016).
Tobiume, K. et al. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2, 222–228 (2001).
Aouadi, M., Binetruy, B., Caron, L., Le Marchand-Brustel, Y. & Bost, F. Role of MAPKs in development and differentiation: lessons from knockout mice. Biochimie 88, 1091–1098 (2006).
Kawarazaki, Y., Ichijo, H. & Naguro, I. Apoptosis signal-regulating kinase 1 as a therapeutic target. Expert Opin. Ther. Targets 18, 651–664 (2014).
Acknowledgements
S.S. is funded by the German Research Foundation (DFG; SCHU 3146/1-1). A.E.F. is supported by the US National Institutes of Health (NIH; grants R01 DK113592, U01 AA022489 and R21AA023574).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
FURTHER INFORMATION
PowerPoint slides
Rights and permissions
About this article
Cite this article
Schuster, S., Feldstein, A. Novel therapeutic strategies targeting ASK1 in NASH. Nat Rev Gastroenterol Hepatol 14, 329–330 (2017). https://doi.org/10.1038/nrgastro.2017.42
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2017.42
This article is cited by
-
Multigram-scale synthesis of GS-4997, an inhibitor of apoptosis signal-regulating kinase 1
Chemical Papers (2023)
-
Mitochondria homeostasis: Biology and involvement in hepatic steatosis to NASH
Acta Pharmacologica Sinica (2022)
-
Innate immune regulatory networks in hepatic lipid metabolism
Journal of Molecular Medicine (2019)